With the availability of targeted and expensive hospital treatments for e.g. cancer and rheumatoid arthritis, a new funding system was introduced in 2006 in order to refund Dutch hospitals. This policy measure allows new therapies to be applied in hospital quickly following registration with a mandatory research requirement for cost-effectiveness in daily practice. We offer a short training on the specifics of this policy and what it can mean for your new product. Please contact us for further information.